SLGL

Sol-GelC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$100.00

+35.6% vs current

Most likely

Base case

45%

Probability

Target price

$72.00

-2.3% vs current

B-

Bear case

30%

Probability

Target price

$40.00

-45.7% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment should stay cautious-to-neutral. Primary-source evidence now supports a cleaner balance-sheet picture after the March 2026 raise, but the setup is still mostly a monitoring story centered on one late-2026 clinical readout, with weak near-term fundamental visibility and a recent pipeline setback outside SGT-610 [#6K-2026-03-24] [#PR-2025-12-17].

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystPost-offering cash reset reduces near-term financing pressureHigh impact

The March 23, 2026 underwritten offering was priced at $72.00 per share for roughly $33.1 million gross proceeds, with proceeds earmarked for SGT-610 development, pre-commercialization, and working capital, which likely lowers immediate financing pressure but leaves dilution fresh in the setup [#6K-2026-03-24].

2026-11-15eventSGT-610 Phase 3 topline data remains the defining value inflectionHigh impact

Management said SGT-610 Phase 3 topline results are expected in the fourth quarter of 2026, after reporting >80% recruitment in April 2025 and later completing enrollment; success would matter disproportionately now that SGT-210 has been deprioritized for Darier disease [#PR-2025-04-17] [#PR-2025-12-17].

2027-03-31catalystHigh-frequency BCC and pre-commercialization optionality can add upside only if Gorlin data workHigh impact

The company continues preparatory work for a potential Phase 3 program in high-frequency BCC and used the March 2026 financing to support SGT-610 pre-commercialization activities, but this optionality depends on successful Gorlin Phase 3 execution and is too early to underwrite aggressively [#PR-2025-12-17] [#6K-2026-03-24].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology